Latest News & Features
article
LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start. 1 May 2012
Americas
When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities. 1 May 2012
Big Pharma
Russia’s life sciences industry is growing rapidly, say Vadim Chagin and Maria Nilova. 1 May 2012
Asia
For the first time in the history of the Indian patent system, a compulsory licence has been granted. Archana Shanker considers the implications. 1 May 2012
Americas
The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes. 1 May 2012
Big Pharma
Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe. 1 January 2012
Biotechnology
The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains. 1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of
IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs. 1 January 2012
Big Pharma
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne. 1 January 2012
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes. 1 January 2012